Choose a language and wait for the translated text.
Novo was first to bring a highly effective βGLP-1 weight-loss injection, Wegovy, β to the β U.S. market, but is under pressure to regain ground lost to Lilly's Zepbound in a business that analysts expect will be worth more than $100 billion βa year by 2030.
